Core Viewpoint - The approval of Perindopril Indapamide tablets by the National Medical Products Administration enhances the product portfolio of the company in the cardiovascular field and strengthens its market competitiveness [1] Group 1 - The company's wholly-owned subsidiary, China National Pharmaceutical Group Industrial Co., Ltd., received the drug registration certificate for Perindopril Indapamide tablets [1] - The drug is a compound tablet consisting of Perindopril tert-butylamine and Indapamide, intended for the treatment of primary hypertension in adults [1] - The projected sales revenue for Perindopril Indapamide tablets in public medical institutions and urban pharmacies across the country in 2024 is estimated to be 269 million yuan [1] Group 2 - The cumulative research and development investment for this project by the company amounts to approximately 18.568 million yuan [1] - The approval of this drug will enrich the company's formulation product line in the cardiovascular sector [1] - The new product is expected to enhance the company's competitiveness in the market [1]

Core Viewpoint - The company Shapais (603168) has received approval from the National Medical Products Administration for its polyethylene glycol eye drops, which can be used to prevent or treat symptoms such as dry eyes, foreign body sensation, and eye fatigue [1] Summary by Relevant Categories Product Approval - The polyethylene glycol eye drops are classified as an ophthalmic preparation with a specification of 1.4% (0.4 ml: 5.6 mg) [1] - The approval signifies a significant milestone for the company in expanding its product offerings in the ophthalmic market [1] Research and Development Investment - The cumulative R&D investment for this product has reached approximately 8.11 million RMB [1] - This investment reflects the company's commitment to developing innovative solutions for eye care [1]